If you are completing Book 8 for BCPS recertification, test sheets must be postmarked by January 17, 2006.

This book is divided into three sections—Chronic Illnesses I, Chronic Illnesses II, and Chronic Illnesses III. You have the option of completing one, two, or all three modules. Please make certain to use a separate PSAP-V answer sheet for each and clearly mark which section you are doing.

Returning the answer sheet for BCPS recertification attests that you have completed the test as an individual effort and not in collaboration with any other individual or group. Failure to complete this test as an individual effort may jeopardize your ability to use PSAP for BCPS recertification.
Welcome from the Editorial Board

On behalf of the Editorial Board of the fifth edition of the Pharmacotherapy Self-Assessment Program (PSAP-V) and the American College of Clinical Pharmacy (ACCP), I would like to congratulate you on your purchase of this invaluable resource. Whether you are a returning subscriber, or a first-time buyer, and whether you purchased PSAP-V for recertification, for continuing education, or to help prepare for board certification, you will undoubtedly find the fifth edition of PSAP to be extremely pertinent to your understanding of pharmacotherapy.

ACCP strives to continuously improve its products. In this regard, PSAP-V has undergone many changes to make it even more useful to subscribers. Like previous editions, PSAP-V is composed of a series of books (11 in total) on topics ranging from cardiology to biostatistics. In this edition, the books have been divided into smaller, more manageable modules. Each book contains up to three modules, and each module contains between two and four chapters. These modules, and the accompanying assessments, can be completed independently—meaning that the subscriber does not necessarily have to read the entire book to get continuing education or recertification credit. The Editorial Board has recognized that being able to obtain credit from PSAP-V in these smaller, bite-sized chunks will benefit busy subscribers.

Another major change in PSAP-V is the use of footnotes to highlight for the reader key literature related to the materials in the text. These footnotes supplement rather than replace the annotated bibliography (which still is included, though it has been shortened).

Although PSAP has always been long recognized for its quality and timeliness, this has not come by happenstance. The PSAP-V Editorial Board has worked hard to ensure the continuing quality of this product. Expert authors have been instructed to write their chapters by calling on their own vast experience in practice, and by conveying not only knowledge of the subject but also the passion that comes from years of dedication to a profession and to serving patients. The PSAP-V review process is extremely rigorous, much more so than traditional textbooks. Each chapter has been subjected to multiple reviews before being printed. In particular, special attention has been paid to the self-assessment questions and answers. This element of PSAP-V is one of the many things that differentiates it from other products and therefore is intensely scrutinized.

The PSAP-V Editorial Board recognizes that further improvements can always be made. We are constantly on the lookout for new and better ways of doing things. For this we can use your help. With each PSAP-V module a set of questions are included for you to provide feedback to the Editorial Board. We highly encourage you to complete these questions. We also encourage to give us your comments directly, via e-mail or phone. You can contact either me or Kristin Povilonis at ACCP. I guarantee that you will not only receive a response, but more importantly, that your input will be carefully considered by the entire Editorial Board.

PSAP is like no other product available in the field of pharmacotherapy. Though it is written in the style of a textbook, it is published quarterly, like a journal. PSAP-V provides the unique combination of highly advanced and contemporary content, a distinctive writing-style that emphasizes practical experience in the care of patients, and extensive continuing education/recertification credit. We hope that you find PSAP-V to be an indispensable part of your professional portfolio.

Glen T. Schumock, Pharm.D., M.B.A., FCCP, BCPS
Chair, PSAP Editorial Board

Acknowledgments

The general format of PSAP is modeled after the American College of Physicians’ Medical Knowledge Self-Assessment Program (MK-SAP), currently in its 13th edition. ACCP gratefully acknowledges the advice and guidance provided by the American College of Physicians in the development of PSAP.

ACCP and the PSAP Editorial Board also wish to express our appreciation to the authors and reviewers. The success of this unique pharmacotherapy self-assessment program is the direct result of the commitment by these outstanding clinical pharmacotherapy specialists.

Development and publication of the first edition of PSAP in 1991 was made possible by an educational grant from Sandoz Pharmaceuticals Corporation. ACCP will be forever grateful for its significant assistance in helping to launch this innovative program.
Editorial Board

Glen T. Schumock, Pharm.D., M.B.A., FCCP, BCPS (Chair)
Director and Associate Professor
Center for Pharmacoeconomic Research
University of Illinois at Chicago
Chicago, Illinois

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Clinical Pharmacy Specialist
Methodist Hospital/Park Nicollet Health Services
Minneapolis, Minnesota

Michelle M. (Chapman) Richardson, Pharm.D., FCCP, BCPS
Clinical Associate Professor
Northeastern University
Special and Scientific Staff

William B. Schwartz, M.D. Division of Nephrology
Tufts—New England Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Judy W.M. Cheng, Pharm.D., FCCP, BCPS
Associate Professor of Pharmacy Practice
Division of Pharmacy Practice
Long Island University
Brooklyn, New York
Clinical Pharmacy Specialist in Cardiology
Mount Sinai Hospital
New York, New York

Katherine Hammond Chessman, Pharm.D., FCCP, BCPS, BCNSP
Associate Professor
Department of Pharmacy and Clinical Sciences
Pediatric Pharmacy Practice Residency Program Director
South Carolina College of Pharmacy
Medical University of South Carolina
Clinical Pharmacy Specialist
Pediatrics/Pediatrics Surgery
MUSC Children’s Hospital
Charleston, South Carolina

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Susan C. Fagan, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Clinical and Administrative Pharmacy
College of Pharmacy
University of Georgia
Adjunct Professor of Neurology
Medical College of Georgia
Augusta, Georgia

Adam B. Jackson, Pharm.D., BCPS
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmacy
Kaiser Permanente—Colorado Region
Denver, Colorado

H. William Kelly, Pharm.D., FCCP, BCPS
Professor Emeritus, Pediatrics and Pharmacy
Department of Pediatrics, School of Medicine
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

R. Chris Rathbun, Pharm.D., BCPS With Added Qualifications in Infectious Diseases
Associate Professor
Clinical and Administrative Sciences, College of Pharmacy
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

David J. Ritchie, Pharm.D., FCCP, BCPS
Clinical Pharmacist in Infectious Diseases
Barnes-Jewish Hospital
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Todd P. Semla, Pharm.D., M.S., FCCP, BCPS
Clinical Pharmacy Specialist
Benefits Management
U.S. Department of Veteran Affairs
Hines, Illinois
Associate Professor
Department of Psychiatry and Behavioral Sciences
The Feinberg School of Medicine
Northwestern University
Chicago, Illinois
Chronic Illnesses I Panel

Editorial Board Liaison
Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Authors
Maureen E. Knell, Pharm.D., BCPS
Clinical Assistant Professor
Division of Pharmacy Practice
School of Pharmacy
University of Missouri—Kansas City
Saint Luke’s Multi-Specialty Clinics
Kansas City, Missouri

Mary Lynn McPherson, Pharm.D., BCPS, CDE
Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Reviewers
The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their careful review of the Book 8 chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
Kanab, Utah

David J. Ritchie, Pharm.D., FCCP, BCPS
Clinical Pharmacist in Infectious Diseases
Barnes-Jewish Hospital
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Barbara McCloskey, Pharm.D., BCPS, CDE
Diabetes Education Coordinator
Diabetes Services
Baylor Health Care System
Irving, Texas

Charles D. Ponte, Pharm.D., BCPS, BC-ADM, CDE
Professor of Clinical Pharmacy and Family Medicine
Schools of Pharmacy and Medicine
Robert C. Byrd Health Sciences Center
West Virginia University
Morgantown, West Virginia

Rheumatology: Osteoarthritis and Rheumatoid Arthritis

Eric J. MacLaughlin, Pharm.D., BCPS
Associate Professor and Division Head of Adult Medicine
Department of Pharmacy Practice
Texas Tech School of Pharmacy
Amarillo, Texas

Michelle M. (Chapman) Richardson, Pharm.D., FCCP, BCPS
Clinical Associate Professor
Northeastern University
Special and Scientific Staff

William B. Schwartz, M.D. Division of Nephrology
Tufts—New England Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

Chronic Pain Management: A Disease-based Approach

Peter J.S. Koo, Pharm.D.
Associate Clinical Professor of Pharmacy
Pharmacist Specialist, Pain Management
Department of Clinical Pharmacy and Pharmaceutical Services
University of California at San Francisco
San Francisco, California
Chronic Illnesses II Panel

Editorial Board Liaison
Teresa S. Dunsworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Authors
Jacquelyn L. Bainbridge, Pharm.D., FCCP
Associate Professor
Department of Clinical Pharmacy and Department of Neurology
University of Colorado Health Sciences Center
Denver, Colorado

Melody Ryan, Pharm.D.
Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Associate Professor
Department of Neurology
University of Kentucky College of Medicine
Clinical Pharmacy Specialist
Pharmacy Service
VA Medical Center
Lexington, Kentucky

Mary L. Wagner, M.S., Pharm.D.
Associate Professor
Ernest Mario School of Pharmacy
Department of Pharmacy Practice and Administration
Rutgers, The State University of New Jersey
Piscataway, New Jersey

Michael Z. Wincor, Pharm.D., BCPP
Associate Professor of Clinical Pharmacy, Psychiatry, and
the Behavioral Sciences
Associate Dean, External Programs
University of Southern California Schools of Pharmacy
and Medicine
Los Angeles, California

Reviewers
The American College of Clinical Pharmacy and the authors
would like to thank the following individuals for their
careful review of the Book 8 chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
Kanab, Utah

Julia Elenbaas, Pharm.D.
Belton, Missouri

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Seizure Disorders in Adults
Janine B. Fourner, Pharm.D., BCPS
Clinical Pharmacist
Pharmacy Clinical Operations
Kaiser Permanente
Martinez, California

James W. McAuley, Ph.D.
Associate Professor
Pharmacy Practice and Neurology
The Ohio State University Colleges of Pharmacy and
Medicine
Columbus, Ohio

Glen T. Schumock, Pharm.D., M.B.A., FCCP, BCPS
Director and Associate Professor
Center for Pharmacoeconomic Research
University of Illinois at Chicago
Chicago, Illinois

Headache
Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Clinical Pharmacy Specialist
Methodist Hospital/Park Nicollet Health Services
Minneapolis, Minnesota

Susan R. Winkler, Pharm.D., BCPS
Assistant Director
Ambulatory Clinical Pharmacy Services
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois College of Pharmacy
Chicago, Illinois

Sleep Disorders
Melissa Blair, Pharm.D., BCPS, CDE
Wilmington, North Carolina

Teresa S. Dunworth, Pharm.D., FCCP, BCPS
Clinical Professor of Clinical Pharmacy
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Cynthia K. Kirkwood, Pharm.D., BCPP
Associate Professor of Pharmacy
Vice Chair of Education
Virginia Commonwealth University
Richmond, Virginia
Chronic Illnesses III Panel

Editorial Board Liaison

Teresa S. Dunsworth, Pharm.D., FCCP, BCPS  
Clinical Professor of Clinical Pharmacy  
Department of Clinical Pharmacy  
West Virginia University School of Pharmacy  
Morgantown, West Virginia

Authors

Nina H. Cheigh, Pharm.D.  
Clinical Associate Professor  
Department of Pharmacy Practice  
University of Illinois College of Pharmacy  
Chicago, Illinois

Edith A. Nutescu, Pharm.D.  
Clinical Associate Professor  
Department of Pharmacy Practice  
University of Illinois College of Pharmacy  
Director  
Antithrombosis Center  
University of Illinois Medical Center  
Chicago, Illinois

Philip T. Rodgers, Pharm.D., BCPS, CDE, CPP  
Clinical Pharmacist  
Duke University Health System  
Clinical Assistant Professor  
University of North Carolina at Chapel Hill  
Director of Pharmacy Education  
Duke Area Health Education Center  
Durham, North Carolina

Karen A. Tisdell, Pharm.D., BCPS, CDE  
Pharmacotherapy Specialist  
Diabetes Health Center  
McGuire VA Medical Center  
Richmond, Virginia

Ann K. Wittkowsky, Pharm.D., CACP, FASHP  
Clinical Professor  
University of Washington School of Pharmacy  
Director, Anticoagulation Services  
University of Washington Medical Center  
Seattle, Washington

Reviewers

The American College of Clinical Pharmacy and the authors would like to thank the following individuals for their careful review of the Book 8 chapters:

Nicola G. Dahl, Pharm.D.  
Medical Writer  
Kanab, Utah

Julia Elenbaas, Pharm.D.  
Belton, Missouri

Mary C. Gurnee, Pharm.D.  
Pharmacist Consultant  
Overland Park, Kansas

Thrombosis: Treatment and Prevention in Patients With Chronic Illness

Todd P. Semla, Pharm.D., BCPS, FCCP  
Clinical Pharmacy Specialist  
Pharmacy Benefits Management and Strategic Health Group  
Department of Veterans Affairs  
Hines, Illinois  
Associate Professor  
Department of Psychiatry and Behavioral Sciences  
The Feinberg School of Medicine  
Northwestern University  
Chicago, Illinois

Daniel M. Witt, Pharm.D., FCCP, BCPS, CACP  
Manager  
Clinical Pharmacy Services  
Kaiser Permanente Colorado  
Aurora, Colorado

Diabetes: Glycemic Control

Oralia Bazaldua, Pharm.D., BCPS  
Associate Professor  
Department of Family and Community Medicine  
The University of Texas Health Science Center at San Antonio  
San Antonio, Texas
Chronic Illnesses III Panel

Katherine Hammond Chessman, Pharm.D., FCCP, BCPS, BCNSP
Associate Professor
Department of Pharmacy and Clinical Sciences
Pediatric Pharmacy Practice Residency Program Director
South Carolina College of Pharmacy
Medical University of South Carolina
Clinical Pharmacy Specialist
Pediatrics/Pediatrics Surgery
MUSC Children’s Hospital
Charleston, South Carolina

Management of the Complications Associated With Diabetes

Susan C. Fagan, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Clinical and Administrative Pharmacy
College of Pharmacy
University of Georgia
Adjunct Professor of Neurology
Medical College of Georgia
Augusta, Georgia

Adam B. Jackson, Pharm.D., BCPS
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmacy
Kaiser Permanente—Colorado Region
Denver, Colorado

Joseph J. Saseen, Pharm.D., FCCP, BCPS
Associate Professor
Departments of Clinical Pharmacy and Family Medicine
University of Colorado Health Sciences Center
Denver, Colorado

Dermatology

H. William Kelly, Pharm.D., FCCP, BCPS
Professor Emeritus, Pediatrics and Pharmacy
Department of Pediatrics, School of Medicine
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

Kelly R. Ragucci, Pharm.D., BCPS, CDE
Associate Professor
Pharmacy and Clinical Sciences/Family Medicine
Medical University of South Carolina
Charleston, South Carolina
Disclosure of Potential Conflicts of Interest

Consultancies: Jacquelyn L. Bainbridge (Pfizer, Ortho McNeil); Dianne M. Brundage (Nabi, employer of spouse or significant other, Abbott, employer of spouse or significant other); Judy Cheng (sanofi-aventis, AstraZeneca, Kos Pharmaceuticals); Teresa S. Dunsworth (Medicaid P&T Board; West Virginia University Hospitals P&T Committee); Janine B. Fournier (Tarascon Pharmacopeia); H. William Kelly (National Institutes of Health, National Heart, Lung, and Blood Institute, Food and Drug Administration; Merck, AstraZeneca, Schering/Key); Peter J.S. Koo (Research Advisory Panel of California, Ortho McNeil); James W. McAuley (Epilepsy Foundation of America); Mary Lynn McPherson (Purdue Pharma, Endo); Edith A. Nutescu (AstraZeneca, Sanofi, Elsevier Science); Charles D. Ponte (National Certification Board for Diabetes Educators, Annals of Pharmacotherapy, APhA); Michelle M. Richardson (National Kidney Foundation, Agency for Health Care Research/Centers for Medicare and Medicaid Services, Amgen); Joseph J. Saseen (ASHP, Tarascon Pocket Pharmacopeia); Glen T. Schumock (Pfizer); Michael Z. Wincor (AstraZeneca); Susan R. Winkler (JCAHO); Ann K. Wittkowsky (The Medicines Company, AstraZeneca, GlaxoSmithKline, Novartis, Boehringer Ingelheim, sanofi-aventis).

Stock Ownership: Dianne M. Brundage (GlaxoSmithKline, equity owned by self and by spouse or significant other; Bristol Myers-Squibb, equity owned by self and by spouse or significant other); Glen T. Schumock (Sios, McKesson HBOC, Sepracor).

Royalties: Cynthia K. Kirkwood (American Pharmaceutical Association, Jobson Medical Information); Ann K. Wittkowsky (Facts and Comparisons Inc.).

Grants: Oralia Bazaldua (Pfizer); H. William Kelly (National Health, Lung, and Blood Institute, GlaxoSmithKline, AstraZeneca); Cynthia K. Kirkwood (GlaxoSmithKline); Eric MacLaughlin (Texas Tech Institute of Healthy Aging); James W. McAuley (Epilepsy Foundation of America); Mary Lynn McPherson (Novartis, Purdue Pharma); Edith A. Nutescu (AstraZeneca); Charles D. Ponte (Purdue Pharma LP); R. Chris Rathbun (Roche, Pharmacia, Bristol-Myers Squibb, Gilead Pharmaceuticals/Agouron Pharmaceuticals); Michelle M. Richardson (QualityMetric and Tufts-New England Medical Center); David J. Ritchie (Pfizer); Philip T. Rodgers (Bayer Diagnostics [now Ascensia], Novartis); Joseph J. Saseen (Forest Labs, Pfizer); Glen T. Schumock (Pfizer, AstraZeneca, National Institutes of Health, Mercy Resource Management, Inc., Pharmacia Corporation, Merck, Tap Pharmaceuticals, Dupont Pharmaceutical, Aventis, Searle); Susan R. Winkler (Illinois Department of Public Health); Ann K. Wittkowsky (Agency for Healthcare Policy and Research).

Honoraria: Jacquelyn L. Bainbridge (Pfizer, Ortho McNeil); Judy Cheng (Scios Inc); H. William Kelly (GlaxoSmithKline, AstraZeneca, Schering/Key, Novartis, Merck); Peter J.S. Koo (PharmMed/PriMed); Mary Lynn McPherson (Purdue Pharma); Edith A. Nutescu (GlaxoSmithKline, sanofi-aventis); Charles D. Ponte (Purdue Pharma); R. Chris Rathbun (GlaxoSmithKline, Agouron); Michelle M. Richardson (Amgen); David J. Ritchie (Pfizer); Philip T. Rodgers (Takeda, Kos Pharmaceuticals); Joseph Saseen (Merck, Forest Labs, Pfizer); Glen T. Schumock (ProCE, Inc.); Karen A. Tisdel (Kos Pharmaceuticals); Michael Z. Wincor (Sanofi-Synthelabo); Susan R. Winkler (Boehringer Ingelheim).

Other: R. Chris Rathbun (spouse or significant other performed contract research for Sanofi, Organon, Pharmacia, Aventis, Pfizer, AstraZeneca); Todd P. Semla (spouse or significant other employed by Abbott).
CONTINUING EDUCATION AND PROGRAM EVALUATION INSTRUCTIONS

Continuing Education Credit: The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacotherapy Self-Assessment Program (PSAP) subscribers can earn 20.5 contact hours of continuing education credit for successfully completing the Chronic Illnesses Book of PSAP-V. The Universal Program Numbers are: Chronic Illnesses I 217-000-05-012-H01, 6.5 contact hours; Chronic Illnesses II 217-000-05-013-H01, 6.0 contact hours; and Chronic Illnesses III 217-000-05-014-H01, 8.0 contact hours.

To receive Continuing Pharmacy Education credit, a PSAP-V answer sheet must be returned for scoring. CE credit will be awarded for test scores 50% or greater. The answers to each CE test will be made available electronically to each participant after he or she has successfully completed the CE test. The answers will arrive with the participant’s statement of credit. Those participants who desire to receive the answers in printed format must waive their opportunity to receive CE credit for any remaining unused CE programs that are included in this book, unless they submit the CE tests for those programs at the same time.

To receive the explained answers to the continuing education questions without submitting a CE test, fill out the top portion of the PSAP Test Answer Sheet for the applicable module and check the waiver statement, which states “Please send me the printed answers for the CE questions in the module indicated above. Because the answer book includes the answers to the other modules in this PSAP book, I waive my ability to submit future CE tests for those modules in this book that I have not submitted at this point.” Answer books will be mailed with the Statements of Credit.

Book 8 Self-Assessment Questions

Directions: The self-assessment questions (items) can be found after each chapter. Each item consists of a question or incomplete statement followed by four lettered answers or completions. Please read each carefully and select the one lettered answer or completion that is best in each case. Completely blacken the corresponding lettered circle on the test question section of the enclosed PSAP-V answer sheet. Each book has two or more modules. Use a separate answer sheet for each module. Only PSAP-V test sheets will be accepted.

Book 8 Subscriber Evaluation

ACCP would like your assistance in evaluating the quality and usefulness of the Chronic Illnesses Book in PSAP-V. Answer sheets, provided with the book, include two sections: the first set of numbers (shaded) for the evaluation questions and next set of numbers for the test questions. Using a separate answer sheet for each module, please complete this evaluation in addition to the self-assessment questions. Indicate your response to the following questions by blackening the corresponding number in the evaluation area of the answer sheet that best represents your assessment.

1 = Definitely agree  2 = Moderately agree  3 = Cannot decide  4 = Moderately disagree  5 = Strongly disagree

Subscriber Evaluation – Chronic Illnesses I
1. The educational content of the material presented was appropriate for a pharmacotherapy specialist.
2. The level of difficulty of material presented was appropriate for a pharmacotherapy specialist.
3. I was satisfied with the content of the program.
4. I was satisfied with the administration of the program.
5. The program achieved its stated educational objectives.

Questions 6–11 apply to the chapter on Chronic Pain Management: A Disease-based Approach
6. The material presented was applicable to my practice.
7. The information presented was accurate and timely.
8. The material provided new information.
9. The material was clearly written.
10. The learning objectives were adequately assessed by the self-assessment questions.
11. The self-assessment questions were written clearly.
Questions 12–17 apply to the chapter on Rheumatology: Osteoarthritis and Rheumatoid Arthritis
12. The material presented was applicable to my practice.
13. The information presented was accurate and timely.
14. The material provided new information.
15. The material was clearly written.
16. The learning objectives were adequately assessed by the self-assessment questions.
17. The self-assessment questions were written clearly.

Subscriber Evaluation – Chronic Illnesses II
1. The educational content of the material presented was appropriate for a pharmacotherapy specialist.
2. The level of difficulty of material presented was appropriate for a pharmacotherapy specialist.
3. I was satisfied with the content of the program.
4. I was satisfied with the administration of the program.
5. The program achieved its stated educational objectives.

Questions 6–11 apply to the chapter on Seizure Disorders in Adults
6. The material presented was applicable to my practice.
7. The information presented was accurate and timely.
8. The material provided new information.
9. The material was clearly written.
10. The learning objectives were adequately assessed by the self-assessment questions.
11. The self-assessment questions were written clearly.

Questions 12–17 apply to the chapter on Headache
12. The material presented was applicable to my practice.
13. The information presented was accurate and timely.
14. The material provided new information.
15. The material was clearly written.
16. The learning objectives were adequately assessed by the self-assessment questions.
17. The self-assessment questions were written clearly.

Questions 18–23 apply to the chapter on Sleep Disorders
18. The material presented was applicable to my practice.
19. The information presented was accurate and timely.
20. The material provided new information.
21. The material was clearly written.
22. The learning objectives were adequately assessed by the self-assessment questions.
23. The self-assessment questions were written clearly.

Subscriber Evaluation – Chronic Illnesses III
1. The educational content of the material presented was appropriate for a pharmacotherapy specialist.
2. The level of difficulty of material presented was appropriate for a pharmacotherapy specialist.
3. I was satisfied with the content of the program.
4. I was satisfied with the administration of the program.
5. The program achieved its stated educational objectives.

Questions 6–11 apply to the chapter on Thrombosis: Treatment and Prevention in Patients with Chronic Illnesses
6. The material presented was applicable to my practice.
7. The information presented was accurate and timely.
8. The material provided new information.
9. The material was clearly written.
10. The learning objectives were adequately assessed by the self-assessment questions.
11. The self-assessment questions were written clearly.
Questions 12–17 apply to the chapter on Diabetes: Glycemic Control
12. The material presented was applicable to my practice.
13. The information presented was accurate and timely.
14. The material provided new information.
15. The material was clearly written.
16. The learning objectives were adequately assessed by the self-assessment questions.
17. The self-assessment questions were written clearly.

Questions 18–23 apply to the chapter on Management of the Complications Associated with Diabetes
18. The material presented was applicable to my practice.
19. The information presented was accurate and timely.
20. The material provided new information.
21. The material was clearly written.
22. The learning objectives were adequately assessed by the self-assessment questions.
23. The self-assessment questions were written clearly.

Questions 24–29 apply to the chapter on Dermatology
24. The material presented was applicable to my practice.
25. The information presented was accurate and timely.
26. The material provided new information.
27. The material was clearly written.
28. The learning objectives were adequately assessed by the self-assessment questions.
29. The self-assessment questions were written clearly.

For any Question you answered 4 or 5, please provide additional information in the Notes section of the answer sheet.

If you would like to provide additional comments, please provide them in the Notes section of the answer sheet.
Role of ACCP

ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of ACCP’s mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP assists pharmacists in successfully sitting for the specialty certification examinations through publications such as the Pharmacotherapy Self-Assessment Program (PSAP). ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, have knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

Role of BPS

The Board of Pharmaceutical Specialties (BPS) is an administratively independent agency started by the American Pharmaceutical Association. BPS is totally separate and distinct from ACCP. The Board of Pharmaceutical Specialties, via its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects related to sitting for specialty certification examinations. PSAP has been approved by BPS for use in BCPS recertification. Questions regarding the number of hours required for BCPS recertification should be directed to:

Board of Pharmaceutical Specialties
2215 Constitution Ave., N.W.
Washington, DC 20037
(202) 429-7591
www.bpsweb.org
# TABLE OF CONTENTS

## Book 8

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>i</td>
</tr>
<tr>
<td>Editorial Board</td>
<td>ii</td>
</tr>
<tr>
<td>Book 8 Panel</td>
<td>iii</td>
</tr>
<tr>
<td>Disclosure of Potential Conflicts of Interest</td>
<td>vii</td>
</tr>
<tr>
<td>Continuing Education and Program Evaluation Instructions</td>
<td>viii</td>
</tr>
<tr>
<td>Roles of ACCP and BPS</td>
<td>xi</td>
</tr>
</tbody>
</table>

## Chronic Illnesses I

CHRONIC PAIN MANAGEMENT: A DISEASE-BASED APPROACH

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Learning Objectives</td>
<td>1</td>
</tr>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Pathophysiology of Pain</td>
<td>2</td>
</tr>
<tr>
<td>Nociceptive Pain</td>
<td>2</td>
</tr>
<tr>
<td>Transduction</td>
<td>2</td>
</tr>
<tr>
<td>Transmission</td>
<td>3</td>
</tr>
<tr>
<td>Perception</td>
<td>3</td>
</tr>
<tr>
<td>Modulation</td>
<td>4</td>
</tr>
<tr>
<td>Inflammatory Pain</td>
<td>4</td>
</tr>
<tr>
<td>Peripheral Sensitization</td>
<td>4</td>
</tr>
<tr>
<td>Phenotypic Switch</td>
<td>4</td>
</tr>
<tr>
<td>Central Sensitization</td>
<td>4</td>
</tr>
<tr>
<td>Neuropathic Pain</td>
<td>5</td>
</tr>
<tr>
<td>Ectopic Excitability</td>
<td>6</td>
</tr>
<tr>
<td>Structured Reorganization</td>
<td>6</td>
</tr>
<tr>
<td>Functional Pain</td>
<td>6</td>
</tr>
<tr>
<td>Analgesics</td>
<td>6</td>
</tr>
<tr>
<td>Nonopioid Analgesics</td>
<td>6</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>6</td>
</tr>
<tr>
<td>Nonsteroidal Anti-inflammatory Drugs</td>
<td>6</td>
</tr>
<tr>
<td>Tramadol</td>
<td>7</td>
</tr>
<tr>
<td>Opioids</td>
<td>7</td>
</tr>
<tr>
<td>Adjuvants</td>
<td>9</td>
</tr>
<tr>
<td>Antiepileptic Drugs</td>
<td>11</td>
</tr>
<tr>
<td>First-generation AEDs</td>
<td>11</td>
</tr>
<tr>
<td>Second-generation AEDs</td>
<td>11</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>12</td>
</tr>
<tr>
<td>Other Second-generation AEDs</td>
<td>12</td>
</tr>
<tr>
<td>Antidepressant Drugs</td>
<td>12</td>
</tr>
<tr>
<td>Tricyclic Antidepressant</td>
<td>12</td>
</tr>
<tr>
<td>Selective Serotonin Reuptake Inhibitors</td>
<td>13</td>
</tr>
<tr>
<td>Serotonin-norepinephrine Reuptake Inhibitors</td>
<td>13</td>
</tr>
<tr>
<td>and Other Antidepressant Drugs</td>
<td>13</td>
</tr>
<tr>
<td>Antiarrhythmic Drugs and Local Anesthetics</td>
<td>13</td>
</tr>
<tr>
<td>Topical and Other Adjunct Analgesics</td>
<td>14</td>
</tr>
<tr>
<td>Capsaicin</td>
<td>14</td>
</tr>
<tr>
<td>Other Adjunctive Analgesics</td>
<td>14</td>
</tr>
<tr>
<td>Assessment of Pain</td>
<td>14</td>
</tr>
<tr>
<td>Pain Screening and Assessment</td>
<td>14</td>
</tr>
<tr>
<td>Knee Pain</td>
<td>15</td>
</tr>
<tr>
<td>Foot Pain</td>
<td>15</td>
</tr>
<tr>
<td>Pathogenesis of V.H.'s Pain</td>
<td>17</td>
</tr>
<tr>
<td>Treatment Plan for V.H.</td>
<td>17</td>
</tr>
<tr>
<td>Painful Diabetic Neuropathy</td>
<td>18</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>18</td>
</tr>
<tr>
<td>Assessment</td>
<td>18</td>
</tr>
<tr>
<td>Management</td>
<td>19</td>
</tr>
<tr>
<td>Post-herpetic Neuralgia</td>
<td>21</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>21</td>
</tr>
<tr>
<td>Assessment</td>
<td>21</td>
</tr>
<tr>
<td>Management</td>
<td>22</td>
</tr>
<tr>
<td>Low Back Pain</td>
<td>23</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>23</td>
</tr>
<tr>
<td>Assessment</td>
<td>24</td>
</tr>
<tr>
<td>Management</td>
<td>28</td>
</tr>
<tr>
<td>Acute LBP</td>
<td>28</td>
</tr>
<tr>
<td>Chronic LBP Management</td>
<td>29</td>
</tr>
<tr>
<td>Chronic Spinal Cord Injury Pain</td>
<td>31</td>
</tr>
</tbody>
</table>
### Table of Contents

- Pathophysiology ............................................. 31
- Assessment ................................................. 31
- Management ................................................ 33
- The Role of the Pharmacist in Chronic Pain Management ............................................. 35
- Annotated Bibliography .................................... 35

### Self-Assessment Questions

- RHEUMATOLOGY: OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
  - Learning Objectives .................................... 41
  - Introduction ............................................. 41
  - Pathophysiology of Osteoarthritis ................... 42
  - Definition and Epidemiology ......................... 42
  - Etiology and Pathophysiologic Findings ............. 42
  - Classification and Risk Factors ...................... 43
  - Clinical Features ....................................... 44
  - Diagnosis ............................................... 44
  - Prognosis ............................................... 44
  - Pathophysiology of Rheumatoid Arthritis ............ 44
  - Definition and Epidemiology ......................... 44
  - Etiology and Pathophysiologic Findings ............. 46
  - Clinical Features ....................................... 47
  - Joint Involvement ...................................... 47
  - Extra-articular Involvement ......................... 48
  - Diagnosis ............................................... 48
  - Prognosis ............................................... 48
  - Quality Patient Care .................................... 49
  - General Therapeutic Goals and Outcomes for Arthritis ............................................. 49
  - Pharmacotherapy ........................................ 49
  - Symptomatic Therapies for Osteoarthritis and Rheumatoid Arthritis: Topical Agents .......... 49
  - Capsaicin .............................................. 49
  - Other Topical Agents ................................... 50
  - Symptomatic Therapies for OA and RA: Systemic Analgesics/Anti-inflammatory Drugs .......... 50
  - Acetaminophen .......................................... 50
  - Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitors ............................................. 51
  - Efficacy of NSAIDs and COX-2 Inhibitors .......... 52
  - Adverse Effects of NSAIDs and COX-2 Inhibitors .... 52
  - Inhibitors .............................................. 52
  - Gastrointestinal Complications ...................... 52
  - Therapeutic Strategies to Reduce the Risk of NSAID-Associated Complications ................. 52
  - Cardiovascular Complications Associated with COX-2 inhibitors and NSAIDs ................. 55
  - Other Adverse Effects of NSAIDs and COX-2 Inhibitors ............................................. 57
  - Considerations for Using NSAIDs and COX-2 Inhibitors ............................................. 58
  - Indication of Therapy ................................... 58
  - Selection of Drugs ..................................... 58
  - Pharmacoeconomic Factors ................................ 59
  - Applying Clinical Judgment ............................. 59
  - Corticosteroids ......................................... 59
  - Intra-articular Injections ................................ 59
  - Systemic Administration of Corticosteroids .......... 61
  - Viscosupplementation ................................... 61
  - Dietary Supplements .................................... 62
  - Glucosamine and Chondroitin .......................... 62
  - Other Dietary Supplement Products .................. 64
  - Opioids and Tramadol ................................... 64
  - Disease-modifying Drugs ............................... 64
  - Disease-modifying Osteoarthritic Drugs .......... 65
  - Disease-modifying Antirheumatic Drugs .......... 65
  - First-tier DMARDs ....................................... 65
  - Hydroxychloroquine ..................................... 65
  - Sulfasalazine ............................................ 66
  - Methotrexate ............................................ 66
  - Leflunomide ............................................. 67
  - Tumor Necrosis Factor Antagonists .................. 68
  - Interleukin-1 Receptor Antagonists ................ 68
  - DMARDs for Special Situations ....................... 69
  - Tetracyclines .......................................... 69
  - Combination DMARD therapy ............................ 69
  - Investigational Drugs for OA and RA ................. 69
  - Nonpharmacological Therapy ........................... 70
  - Rest and Exercise ....................................... 70
  - Nutrition, Weight Loss, and Dietary Therapy .......... 70
  - Other Measures to Decrease Pain and/or Enhance Functional Ability ......................... 70
  - Treatment Plan .......................................... 71
  - Algorithms and Guidelines ............................. 71
  - Osteoarthritis .......................................... 71
  - Rheumatoid Arthritis .................................... 71
  - Treatments in Special Populations .................... 71
  - Geriatric Patients ...................................... 71
  - Women of Childbearing Age ............................ 72
  - Patients Taking DMARDs and Implications for Vaccinations ............................................. 74
  - Treatment Outcomes and Monitoring .................. 74
  - Monitoring Outcomes in OA ............................ 74
  - Monitoring Outcomes in RA ............................ 75
  - Monitoring of Drug Therapy in Arthritis ............ 75
  - NSAIDs .................................................. 75
  - DMARDs .................................................. 75
  - Corticosteroids ......................................... 76
  - Patient Education ......................................... 76
  - Arthritis Self-management ............................... 76
  - Drug Therapy ............................................. 76
  - Quality Improvement: The Pharmacist’s Role ........ 76
  - Efficiency ................................................. 76
  - Efficacy and Effectiveness .............................. 76
  - Conclusion ................................................ 79
  - Annotated Bibliography ................................... 79

### Self-Assessment Questions

- The Role of the Pharmacist in Chronic Pain Pharmacotherapy ................................. 49
- General Therapeutic Goals and Outcomes for Arthritis ............................................. 49
- Pharmacotherapy ............................................. 49
- Symptomatic Therapies for Osteoarthritis and Rheumatoid Arthritis: Topical Agents .......... 49
- Capsaicin .............................................. 49
- Other Topical Agents ................................... 50
- Symptomatic Therapies for OA and RA: Systemic Analgesics/Anti-inflammatory Drugs .......... 50
- Acetaminophen .......................................... 50
- Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitors ............................................. 51
- Efficacy of NSAIDs and COX-2 Inhibitors .......... 52
- Adverse Effects of NSAIDs and COX-2 Inhibitors .... 52
- Inhibitors .............................................. 52
- Gastrointestinal Complications ...................... 52
- Therapeutic Strategies to Reduce the Risk of NSAID-Associated Complications ................. 52
- Cardiovascular Complications Associated with COX-2 inhibitors and NSAIDs ................. 55
- Other Adverse Effects of NSAIDs and COX-2 Inhibitors ............................................. 57
- Considerations for Using NSAIDs and COX-2 Inhibitors ............................................. 58
- Indication of Therapy ................................... 58
- Selection of Drugs ..................................... 58
- Pharmacoeconomic Factors ................................ 59
- Applying Clinical Judgment ............................. 59
- Corticosteroids ......................................... 59
- Intra-articular Injections ................................ 59
- Systemic Administration of Corticosteroids .......... 61
- Viscosupplementation ................................... 61
- Dietary Supplements .................................... 62
- Glucosamine and Chondroitin .......................... 62
- Other Dietary Supplement Products .................. 64
- Opioids and Tramadol ................................... 64
- Disease-modifying Drugs ............................... 64
- Disease-modifying Osteoarthritic Drugs .......... 65
- Disease-modifying Antirheumatic Drugs .......... 65
- First-tier DMARDs ....................................... 65
- Hydroxychloroquine ..................................... 65
- Sulfasalazine ............................................ 66
- Methotrexate ............................................ 66
- Leflunomide ............................................. 67
- Tumor Necrosis Factor Antagonists .................. 68
- Interleukin-1 Receptor Antagonists ................ 68
- DMARDs for Special Situations ....................... 69
- Tetracyclines .......................................... 69
- Combination DMARD therapy ............................ 69
- Investigational Drugs for OA and RA ................. 69
- Nonpharmacological Therapy ........................... 70
- Rest and Exercise ....................................... 70
- Nutrition, Weight Loss, and Dietary Therapy .......... 70
- Other Measures to Decrease Pain and/or Enhance Functional Ability ......................... 70
- Treatment Plan .......................................... 71
- Algorithms and Guidelines ............................. 71
- Osteoarthritis .......................................... 71
- Rheumatoid Arthritis .................................... 71
- Treatments in Special Populations .................... 71
- Geriatric Patients ...................................... 71
- Women of Childbearing Age ............................ 72
- Patients Taking DMARDs and Implications for Vaccinations ............................................. 74
- Treatment Outcomes and Monitoring .................. 74
- Monitoring Outcomes in OA ............................ 74
- Monitoring Outcomes in RA ............................ 75
- Monitoring of Drug Therapy in Arthritis ............ 75
- NSAIDs .................................................. 75
- DMARDs .................................................. 75
- Corticosteroids ......................................... 76
- Patient Education ......................................... 76
- Arthritis Self-management ............................... 76
- Drug Therapy ............................................. 76
- Quality Improvement: The Pharmacist’s Role ........ 76
- Efficiency ................................................. 76
- Efficacy and Effectiveness .............................. 76
- Conclusion ................................................ 79
- Annotated Bibliography ................................... 79
Pharmacotherapy Self-Assessment Program, 5th Edition

Table of Contents

**Chronic Illnesses II**

SEIZURE DISORDERS IN ADULTS

- Learning Objectives ........................................ 91
- Introduction ................................................... 91
- Pathophysiology .............................................. 91
- Definitions ...................................................... 91
- Etiology .......................................................... 92
- Clinical Characteristics ...................................... 93
- Diagnosis ......................................................... 93
- History/Examination .......................................... 93
- Radiological Evaluation ...................................... 93
- Laboratory Evaluation ........................................ 93
- Electroencephalography ...................................... 94
- Epidemiology .................................................... 94
- Prognosis ........................................................ 94
- Therapeutic Goals/Outcomes .................................. 95
- Quality Patient Care .......................................... 95
- Pharmacotherapy ............................................... 95
- Therapy Initiation ............................................. 95
- Pharmacotherapy Refinements ................................. 96
- Common Severe Adverse Effects/Interactions/Therapeutic Contraindications ........................................... 98
- Nonpharmacological Therapy ................................ 98
- Resection ......................................................... 98
- Vagus Nerve Stimulation ..................................... 100
- Treatment Plan ................................................ 100
- Therapeutic End Points ....................................... 100
- Guidelines and Algorithm .................................... 101
- Scottish Intercollegiate Guidelines Network ............. 101
- National Institute for Clinical Excellence ................. 101
- Prescribing Rationally using Decision support ......... 102
- In General practice study ..................................... 102
- Agency for Healthcare Research and Quality Evidence Report ................................................... 102
- American Academy of Neurology Practice Parameters ................................................................. 103
- Effectiveness ...................................................... 103
- Treatments of Choice in Special Populations ........... 103
- Women with Epilepsy .......................................... 103
- Decreased Fertility ............................................. 103
- Risk of Congenital Anomalies and Malformations ....... 103
- Management During Pregnancy ............................. 104
- Postpartum Management ..................................... 104
- Contraception .................................................... 104
- Catamenial Epilepsy ............................................ 104
- Elderly .............................................................. 105
- Physiological Changes ......................................... 105
- Comorbid Conditions .......................................... 105
- Adverse Effects .................................................. 105
- Discontinuation of an AED in Seizure-free Patients .... 105
- Monitoring .......................................................... 105
- Therapeutic Drug Monitoring .................................. 106
- Bone Effects ...................................................... 106

- Hypersensitivity .............................................. 106
- Adherence ......................................................... 107
- System Support for Medication Use Process ............. 107
- Documentation That the Pharmacist Should Perform ................................................................. 107
- Patient Education ............................................... 107
- Reducing the Patient’s Perceived Burden of Illness ................................................................. 108
- Assuring That the Patient’s Goals of Therapy are Met ................................................................. 108
- Special Directions and Precautions for Drug Preparation, Administration, and Use by the Patient ................................................................. 109
- Drug Costs ......................................................... 109
- Specific Issues Related to Drug or Disease-state Counseling in Different Patient Populations ........... 109
- Quality Improvement .......................................... 110
- Conclusion ......................................................... 110
- Annotated Bibliography ....................................... 110
- Self-Assessment Questions .................................... 113

HEADACHE

- Learning Objectives .......................................... 117
- Introduction ...................................................... 117
- Tension-type Headache ....................................... 118
- Pathophysiology ............................................... 118
- Clinical Presentation ......................................... 118
- Diagnosis ........................................................ 118
- Treatment Goals ................................................. 118
- Nonpharmacological Therapy ................................ 119
- Pharmacological Therapy .................................... 119
- Patient Education ............................................... 119
- Migraine Headache ............................................ 119
- Pathophysiology ............................................... 119
- Clinical Presentation ......................................... 120
- Migraine with Aura ............................................ 120
- Migraine Without Aura ....................................... 121
- Probable Migraine ............................................. 121
- Status Migrainosus ............................................. 121
- Diagnosis ........................................................ 121
- Treatment Goals ................................................. 121
- Nonpharmacological Therapy ................................ 122
- Pharmacological Therapy .................................... 122
- Drug Management of the Acute Attack .................... 122
- Nonspecific Treatment ...................................... 122
- Specific Treatment ............................................. 123
- Ergotamines and Dihydroergotamines ..................... 123
- Triptans ............................................................ 124
- Selection of a Triptan ......................................... 124
- Dosing of the Triptans ........................................ 125
- Prevention ......................................................... 125
- General Considerations when Starting a Preventive Drug ................................................................. 125
- Antiepileptic Drugs .............................................. 126
- ß-Blockers ........................................................ 126
- Antidepressant Drugs .......................................... 126

Tension-type Headache

- Introduction ...................................................... 117
- Clinical Presentation ......................................... 118
- Pathophysiology ............................................... 118
- Diagnosis ........................................................ 118
- Treatment Goals ................................................. 118
- Nonpharmacological Therapy ................................ 119
- Pharmacological Therapy .................................... 119
- Patient Education ............................................... 119
- Migraine Headache ............................................ 119
- Pathophysiology ............................................... 119
- Clinical Presentation ......................................... 120
- Migraine with Aura ............................................ 120
- Migraine Without Aura ....................................... 121
- Probable Migraine ............................................. 121
- Status Migrainosus ............................................. 121
- Diagnosis ........................................................ 121
- Treatment Goals ................................................. 121
- Nonpharmacological Therapy ................................ 122
- Pharmacological Therapy .................................... 122
- Drug Management of the Acute Attack .................... 122
- Nonspecific Treatment ...................................... 122
- Specific Treatment ............................................. 123
- Ergotamines and Dihydroergotamines ..................... 123
- Triptans ............................................................ 124
- Selection of a Triptan ......................................... 124
- Dosing of the Triptans ........................................ 125
- Prevention ......................................................... 125
- General Considerations when Starting a Preventive Drug ................................................................. 125
- Antiepileptic Drugs .............................................. 126
- ß-Blockers ........................................................ 126
- Antidepressant Drugs .......................................... 126
# Table of Contents

- Calcium Channel Blockers .......................... 127
- Other Drugs ........................................ 127
- Patient-specific Treatment for Migraine .......... 127
- Treatments Based on Clinical Situation .......... 127
- Patient Education .................................. 127
- Acute and Preventive Administration, Precautions ........................................ 127
- Drug-drug Interactions ................................ 128
- Monitoring ........................................... 128
- Cluster Headache .................................... 128
- Pathophysiology ...................................... 128
- Clinical Presentation ................................ 129
- Diagnosis ............................................. 129
- Treatment Goals ..................................... 129
- Nonpharmacological Therapy ......................... 129
- Pharmacological Therapy ............................ 129
- Acute .................................................. 129
- Preventive ............................................ 130
- Short-term Preventives ................................ 130
- Corticosteroids ....................................... 130
- Methysergide ......................................... 130
- Ergotamine ............................................ 130
- Long-term Preventives ................................ 130
- Verapamil ............................................. 130
- Lithium Carbonate ..................................... 130
- Antiepileptic Drugs .................................... 130
- Melatonin ............................................. 130
- Patient-specific Treatment .......................... 130
- Patient Education .................................... 131
- Other Trigeminal Autonomic Cephalgias .......... 131
- Pathophysiology ...................................... 131
- Paroxysmal Hemianria ................................ 131
- Short-lasting Unilateral Neuralgiform Headache ........................................ 131
- Attacks with Conjunctival Injection and Tearing ........................................ 131
- Cervicogenic Headache ................................ 131
- Temporomandibular Joint Dysfunction ............. 131
- Clinical Presentation ................................ 131
- Diagnosis ............................................. 131
- Treatment Goals ..................................... 132
- Pharmacological Therapy ............................ 132
- Patient Education .................................... 132
- Other Primary Headaches ............................ 132
- Pathophysiology ...................................... 132
- Clinical Presentation ................................ 132
- Diagnosis ............................................. 132
- Chronic Transformed Migraine ....................... 132
- Chronic-tension Type Headache ...................... 132
- New Daily Persistent Headache ....................... 132
- Treatment Goals ..................................... 133
- Pharmacological and Nonpharmacological Therapy ........................................ 133
- Chronic Daily Headache with Drug Overuse in the Outpatient Setting .................. 133
- Chronic Daily Headache with Drug Overuse and Admitted for Inpatient Detoxification ........................................ 133
- Behavior Treatment ................................... 135
- Acute Therapy ........................................ 135
- Preventive Therapy ................................... 135
- Other Therapy ........................................ 135
- Patient Education .................................... 135
- Medication Overuse Headache ....................... 135
- Conclusion ............................................ 135
- Annotated Bibliography ............................... 135

## Self-Assessment Questions

### SLEEP DISORDERS

- Learning Objectives ................................ 141
- Introduction ......................................... 141
- Definition ............................................ 141
- Sleep Stages and Sleep Architecture .............. 141
- Function of Normal Sleep and Consequences of Abnormal Sleep .......................... 142
- Neurochemistry of Sleep ............................. 142
- Acetylcholine ........................................ 143
- Norepinephrine ...................................... 143
- Histamine ............................................ 143
- Serotonin ............................................. 143
- Dopamine ............................................. 143
- Orexin ................................................ 143
- Adenosine ............................................ 143
- Gamma-aminobutyric Acid ........................... 144
- Classification of Sleep Disorders .................. 144
- Diagnosing, Assessing, and Monitoring of Sleep Disorders .......................... 145
- Subjective Tests ..................................... 145
- Objective Tests ...................................... 146
- Therapeutic Goals and End Points ................... 147
- Insomnia ............................................. 147
- Definition and Consequences of Poor Sleep ....... 147
- Economic Impact ..................................... 147
- Epidemiology ........................................ 147
- Classification and Assessment of Insomnia ....... 147
- Treatment ............................................. 148
- Nonpharmacological Treatment ....................... 148
- Sleep Hygiene Education ............................. 148
- Relaxation Therapy ................................... 148
- Stimulus Control ..................................... 148
- Sleep Restriction ..................................... 148
- Cognitive Restructuring .............................. 149
- Bright Light Therapy ................................ 149
- Pharmacological Treatment ........................ 149
- Benzodiazepine Receptor Agonists ................. 149
- Memory Impairment and Anterograde Amnesia ........................................ 150
- Tolerance ............................................. 151
- Withdrawal and Rebound ............................. 151
- Physiological Dependence ............................ 151
- Respiratory Depression ................................ 152
- Cautions .............................................. 152
- Drug Interactions .................................... 152
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taper Plan</td>
<td>152</td>
</tr>
<tr>
<td>Drugs Recently Approved, Awaiting Approval, or Under Investigation</td>
<td>153</td>
</tr>
<tr>
<td>Eszopiclone</td>
<td>153</td>
</tr>
<tr>
<td>Ramelteon</td>
<td>153</td>
</tr>
<tr>
<td>Other</td>
<td>153</td>
</tr>
<tr>
<td>Antidepressant Drugs</td>
<td>153</td>
</tr>
<tr>
<td>Antihistamine Drugs</td>
<td>154</td>
</tr>
<tr>
<td>Antipsychotic Drugs</td>
<td>154</td>
</tr>
<tr>
<td>Herbal and Supplement Therapies</td>
<td>155</td>
</tr>
<tr>
<td>Melatonin</td>
<td>155</td>
</tr>
<tr>
<td>Valerian</td>
<td>156</td>
</tr>
<tr>
<td>Treatment Guidelines</td>
<td>156</td>
</tr>
<tr>
<td>Patient Education</td>
<td>157</td>
</tr>
<tr>
<td>Quality Improvement</td>
<td>157</td>
</tr>
<tr>
<td>Hypersomnolent Sleep Disorders</td>
<td>158</td>
</tr>
<tr>
<td>Sleep Apnea</td>
<td>158</td>
</tr>
<tr>
<td>Obstructive Sleep Apnea</td>
<td>158</td>
</tr>
<tr>
<td>Central Sleep Apnea</td>
<td>159</td>
</tr>
<tr>
<td>Narcolepsy</td>
<td>159</td>
</tr>
<tr>
<td>Description</td>
<td>159</td>
</tr>
<tr>
<td>Treatment</td>
<td>159</td>
</tr>
<tr>
<td>Sleep-related Movement Disorders</td>
<td>160</td>
</tr>
<tr>
<td>Restless Legs Syndrome</td>
<td>160</td>
</tr>
<tr>
<td>Description and Epidemiology</td>
<td>160</td>
</tr>
<tr>
<td>Treatment</td>
<td>160</td>
</tr>
<tr>
<td>Periodic Limb Movements of Sleep</td>
<td>161</td>
</tr>
<tr>
<td>Conclusion</td>
<td>161</td>
</tr>
<tr>
<td>Annotated Bibliography</td>
<td>161</td>
</tr>
<tr>
<td>Self-Assessment Questions</td>
<td>163</td>
</tr>
</tbody>
</table>

**Chronic Illnesses III**

**THROMBOSIS: TREATMENT AND PREVENTION IN PATIENTS WITH CHRONIC ILLNESSES**

<table>
<thead>
<tr>
<th>Learning Objectives</th>
<th>169</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>169</td>
</tr>
<tr>
<td>Preventing Venous Thromboembolism in Hospitalized Medically Ill Patients</td>
<td>171</td>
</tr>
<tr>
<td>Preventing VTE in Orthopedic Surgery</td>
<td>171</td>
</tr>
<tr>
<td>Pharmacological Options and Comparative Outcomes</td>
<td>172</td>
</tr>
<tr>
<td>Total Hip Replacement Surgery</td>
<td>172</td>
</tr>
<tr>
<td>Total Knee Replacement Surgery</td>
<td>173</td>
</tr>
<tr>
<td>Hip Fracture Surgery</td>
<td>174</td>
</tr>
<tr>
<td>Timing of Prophylaxis Initiation</td>
<td>174</td>
</tr>
<tr>
<td>Prophylactic Therapy Duration</td>
<td>175</td>
</tr>
<tr>
<td>Preventing and Treating VTE in Patients with Hypercoagulable Conditions</td>
<td>175</td>
</tr>
<tr>
<td>Therapy Duration in Patients with Hypercoagulable Conditions</td>
<td>176</td>
</tr>
<tr>
<td>Primary Prophylaxis in Asymptomatic Carriers</td>
<td>176</td>
</tr>
<tr>
<td>Oral Contraceptive Use in Patients with Thrombophilia</td>
<td>177</td>
</tr>
<tr>
<td>Preventing and Treating VTE in Patients with a Malignancy</td>
<td>177</td>
</tr>
</tbody>
</table>

| VTE Prevention in Malignancy                                      | 177  |
| VTE Treatment in Malignancy                                      | 178  |
| Anticoagulant Use in Malignancy                                  | 179  |
| Monitoring Considerations                                        | 180  |
| Obesity                                                          | 180  |
| Renal Impairment                                                 | 181  |
| Managing Anticoagulation in Patients Undergoing Invasive Procedures | 182  |
| Evaluating Thrombosis Risk                                       | 182  |
| Evaluating Bleeding Risk                                         | 183  |
| Clinical and Practical Considerations in Designing a Bridge Therapy Plan | 184  |
| Conclusion                                                       | 185  |
| Annotated Bibliography                                           | 185  |
| Self-Assessment Questions                                         | 187  |

**DIABETES: GLYCEMIC CONTROL**

<table>
<thead>
<tr>
<th>Learning Objectives</th>
<th>193</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>193</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>193</td>
</tr>
<tr>
<td>Nomenclature</td>
<td>194</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>194</td>
</tr>
<tr>
<td>Type 2 Diabetes Mellitus</td>
<td>194</td>
</tr>
<tr>
<td>Type 1 Diabetes Mellitus</td>
<td>195</td>
</tr>
<tr>
<td>Gestational Diabetes Mellitus and Other Forms</td>
<td>195</td>
</tr>
<tr>
<td>Screening</td>
<td>195</td>
</tr>
<tr>
<td>Prevention of Diabetes Mellitus</td>
<td>196</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>197</td>
</tr>
<tr>
<td>Treatment Goals</td>
<td>198</td>
</tr>
<tr>
<td>Quality Patient Care</td>
<td>198</td>
</tr>
<tr>
<td>Lifestyle Management</td>
<td>198</td>
</tr>
<tr>
<td>Diet Management: An Evidence-based Approach</td>
<td>198</td>
</tr>
<tr>
<td>Exercise and Activity</td>
<td>198</td>
</tr>
<tr>
<td>Stress and Depression Management</td>
<td>199</td>
</tr>
<tr>
<td>Pharmacotherapy</td>
<td>199</td>
</tr>
<tr>
<td>Nonsulfonylurea Secretagogues</td>
<td>199</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>200</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>200</td>
</tr>
<tr>
<td>Clinical Application</td>
<td>200</td>
</tr>
<tr>
<td>Adverse Events and Other Clinical Effects</td>
<td>201</td>
</tr>
<tr>
<td>New Rapid-acting Insulins</td>
<td>201</td>
</tr>
<tr>
<td>Clinical Application</td>
<td>202</td>
</tr>
<tr>
<td>New Long-acting Insulins</td>
<td>202</td>
</tr>
<tr>
<td>Clinical Application</td>
<td>202</td>
</tr>
<tr>
<td>Emerging Therapies</td>
<td>203</td>
</tr>
<tr>
<td>Inhaled Insulin</td>
<td>203</td>
</tr>
<tr>
<td>Glucagon-like Peptide-1 Agonists</td>
<td>204</td>
</tr>
<tr>
<td>DPP-IV Inhibitors</td>
<td>204</td>
</tr>
<tr>
<td>Pramlintide</td>
<td>204</td>
</tr>
<tr>
<td>Dual PPAR Agonists</td>
<td>204</td>
</tr>
<tr>
<td>Treatment Plan</td>
<td>205</td>
</tr>
<tr>
<td>Monitoring</td>
<td>206</td>
</tr>
<tr>
<td>Traditional Blood Glucose Monitors</td>
<td>206</td>
</tr>
<tr>
<td>Nontraditional Monitors</td>
<td>206</td>
</tr>
<tr>
<td>Patient Education</td>
<td>207</td>
</tr>
<tr>
<td>Low Literacy Issues</td>
<td>207</td>
</tr>
</tbody>
</table>
Table of Contents

Self-management Education ........................................ 207
Quality Improvement ............................................. 208
The Healthy People 2010 Report on Diabetes ................. 208
Research End Points and Quality of Life Indicators .......... 208
Summary .......................................................... 209
Annotated Bibliography ........................................... 210
Self-Assessment Questions ....................................... 213

MANAGEMENT OF THE COMPLICATIONS
ASSOCIATED WITH DIABETES
Learning Objectives ................................................ 219
Introduction ....................................................... 219
Pathophysiology of Chronic Complications ..................... 219
Microvascular Complications .................................. 220
Oxidative Stress .................................................. 220
Advanced Glycation End Products ............................... 220
Aldose Reductase (Polyol) Pathway .............................. 220
Hexosamine Pathway ............................................ 221
Protein Kinase C .................................................. 221
Hormones, Cytokines, Growth Factors, and Vasomotor Mediators ............................................ 221
Inflammation ..................................................... 221
Macrovascular Complications .................................. 221
Abnormal Lipoproteins .......................................... 222
Prothrombosis ..................................................... 222
Overall Risk of Developing Chronic Complications ......... 222
Microvascular Complications .................................. 223
Macrovascular Complications .................................. 223
General Management for the Prevention of Complications ............................................ 223
Glycemic Control .................................................. 223
Postprandial Hyperglycemia .................................... 225
Blood Pressure Control .......................................... 225
Lipid Control ....................................................... 226
Multifactorial Approach ......................................... 226
Patient Education .................................................. 227
Chronic Complications .......................................... 227
Microvascular ...................................................... 227
Retinopathy ........................................................ 227
Stages of Retinopathy .......................................... 227
Assessment ......................................................... 228
Management ....................................................... 228
Glycemic Control .................................................. 228
Blood Pressure Control .......................................... 228
Other Interventions .............................................. 229
Surgery ............................................................ 229
Nephropathy ......................................................... 229
Assessment ......................................................... 230
Microalbuminuria .................................................. 230
Macroalbuminuria .................................................. 230
Chronic Kidney Failure .......................................... 230
Management ....................................................... 230
Blood Pressure Control .......................................... 230
ACE Inhibitors Versus ARBs .................................... 231
Protein Restriction ................................................ 231
Neuropathy ........................................................ 232

Autonomic .......................................................... 232
Cardiovascular .................................................... 233
Gastrointestinal .................................................... 233
Genitourinary ....................................................... 233
Other .............................................................. 234
Sensorimotor (Peripheral) ....................................... 234
Assessment ......................................................... 234
Management of Painful Neuropathy ............................ 236
Foot Ulcers ........................................................ 236
Prevention and Management .................................... 236
Macrovascular Complications .................................. 237
Management ....................................................... 238
Dyslipidemia ....................................................... 238
Hypertension ....................................................... 239
Aspirin ............................................................. 240
Other Preventive Modalities .................................... 240
Special Populations ................................................ 240
Latent Autoimmune Diabetes in Adults ..................... 240
Pregnancy .......................................................... 240
Elderly .............................................................. 241
Children ............................................................ 241
Patient Quality Improvement .................................... 241
Conclusion .......................................................... 242
Annotated Bibliography .......................................... 242
Self-Assessment Questions ....................................... 245

DERMATOLOGY
Learning Objectives ................................................ 251
Introduction ......................................................... 251
Acne Vulgaris ...................................................... 251
Pathophysiology .................................................... 251
Classification ....................................................... 252
Topical Acne Therapy ............................................. 252
Benzoyl Peroxide ................................................... 252
Azelaic Acid .......................................................... 252
Salicylic Acid and Sulfur ......................................... 253
Retinoids ............................................................ 253
Antibacterial Agents ............................................... 253
Systemic Acne Therapy .......................................... 253
Oral Antibiotic Drugs ............................................. 254
Oral Isotretinoin .................................................... 254
Systemic Hormonal Therapy .................................... 255
Patient Education/Counseling ................................... 255
Psoriasis .............................................................. 256
Pathophysiology .................................................... 256
Topical Therapy ..................................................... 256
Emollients and Keratolytics ...................................... 256
Anthralin ............................................................. 256
Coal Tar ............................................................. 257
Corticosteroids ..................................................... 257
Calcipotriene ....................................................... 257
Tazarotene .......................................................... 257
Systemic Therapy .................................................. 258
Methotrexate ........................................................ 258
Cyclosporine ......................................................... 258
Acitretin ............................................................. 259